Purple Biotech Announces New Preclinical Data for IM1240
Purple Biotech announced new preclinical data supporting the clinical potential of IM1240, the company's lead CAPTN-3 tri-specific antibody. IM1240 is a conditionally activated, capped-CD3x5T4xNKG2A tri-specific designed to direct tumor-selective T-cell activation while also leveraging NKG2A-mediated checkpoint inhibition to enhance anti-tumor activity. The new data demonstrated potent anti-tumor activity for IM1240 across multiple treatment-resistant patient-derived tumor samples. All seven tested samples responded to IM1240 treatment, including samples from PD-1 or PD-1/chemo-resistant head and neck squamous cell carcinoma metastatic lymph nodes and enfortumab vedotin + PD-1-resistant muscle-invasive bladder cancer.
